Mizuho Reiterates Outperform Rating on AxoGen, Inc. (AXGN)

Mizuho analyst Anthony Petrone reiterated an Outperform rating and $40.00 price target on AxoGen, Inc. (NASDAQ: AXGN).

The analyst comments "Late yesterday, AXGN announced that it secured the long awaited BLA license for its flagship Avance Nerve Allograft culminating a process that began nearly 10-years ago. Importantly, the BLA license comes with a broad label covering all peripheral nerve injuries that are currently encompassed by the existing tissue cellular framework. Timelines call for a launch of Avance as a biologic by 2Q:26 which we see opening the potential for significantly wider-scale use across Extremities and Breast over the near-term. Clearance also calls for ongoing post market surveillance studies to be conducted although size and scope is not clear at this juncture. Favorable outcome supports near-term upward re-rate and our OP thesis. Our $40 PT prices AXGN shares at 5.0x our blended 2-year sales outlook ('26E-'27E) while our $50 bull case contemplates higher share scenarios in Breast & Prostate."

For an analyst ratings summary and ratings history on AxoGen, Inc. click here. For more ratings news on AxoGen, Inc. click here.

Shares of AxoGen, Inc. closed at $28.33 yesterday.

You May Also Be Interested In